Innovation Pharmaceuticals Inc (IPIX)

[F1ash]

I imagine the numbness and tingling will still be there. It was prevalent in the first Phase 2 trial. It is just not a severe event.



"All three Brilacidin treatment arms (two single-dose regimens and one three-day dose regimen) reached the primary endpoint, with the clinical success rate for each dosing regimen statistically comparable to the clinical success rate of the FDA-approved seven-day dosing regimen of daptomycin. All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator" - See more at: http://cellceutix.com/brilacidin/#sthash.4fdwlJiV.dpuf